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Although combination therapy with antimicrobial agents is often used, no available method explains or
predicts the efficacies of these combinations satisfactorily. Since the efficacies of antimicrobial agents can be
described by pharmacodynamic indices (PDIs), such as area under the concentration-time curve (AUC), peak
level, and the time that the concentration is above the MIC (time>MIC), it was hypothesized that the same
PDIs would be valid in explaining efficacy during combination therapy. Twenty-four-hour efficacy data (num-
bers of CFU) for Pseudomonas aeruginosa in a neutropenic mouse thigh model were determined for various
combination regimens: ticarcillin-tobramycin (n 5 41 different regimens), ceftazidime-netilmicin (n 5 60),
ciprofloxacin-ceftazidime (n 5 59), netilmicin-ciprofloxacin (n 5 38) and for each of these agents given singly.
Multiple regression analysis was used to determine the importance of various PDIs (time>MIC, time>0.253
the MIC, time>43 the MIC, peak level, AUC, AUC/MIC, and their logarithmically transformed values) during
monotherapy and combination therapy. The PDIs that best explained the efficacies of single-agent regimens
were time>0.253 the MIC for beta-lactams and log AUC/MIC for ciprofloxacin and the aminoglycosides. For
the combination regimens, regression analysis showed that efficacy could best be explained by the combination
of the two PDIs that each best explained the response for the respective agents given singly. A regression model
for the efficacy of combination therapy was developed by use of a linear combination of the regression models
of the PDI with the highest R2 for each agent given singly. The model values for the single-agent therapies were
then used in that equation, and the predicted values that were obtained were compared with the experimental
values. The responses of the combination regimens could best be predicted by the sum of the responses of the
single-agent regimens as functions of their respective PDIs (e.g., time>0.253 the MIC for ticarcillin and log
AUC/MIC for tobramycin). The relationship between the predicted response and the observed response for the
combination regimens may be useful for determination of the presence of synergism. We conclude that the
PDIs for the individual drugs used in this study are class dependent and predictive of outcome not only when
the drugs are given as single agents but also when they are given in combination. When given in combination,
there appears to be a degree of synergism independent of the dosing regimen applied.
Since the advent of antimicrobial agents, methods that de-
scribe and predict the efficacies of the use of these agents in
combination have been sought (1, 2, 7, 12, 14, 16, 20, 28). In
most attempts the results of in vitro experiments have been
applied to predict in vivo efficacy, for instance, by using check-
erboards and/or time-kill curves (5, 6, 13, 14, 26). However,
these in vitro methods are limited by the fact that they measure
effects at static concentrations only, while in vivo concentra-
tions fluctuate over a wide range due to different dosing regi-
mens, absorption rates, and elimination rates. In addition,
combination therapy also results in continuous variations in
the concentration ratios of the two (or more) agents. Several
attempts have recently been made to define some kind of
universal predictor of efficacy or method for determination of
the efficacy of combination therapy in both in vitro (3, 4, 9, 13,
24) and in vivo models (17, 21, 24).
For antimicrobial agents given singly, it is now recognized
that their antibacterial activities are dependent on the dosing
regimen (22, 27). For instance, while the efficacies of beta-
lactam antibiotics are primarily dependent on the time that the
concentration remains above the MIC (time.MIC) and there-
fore the frequency of dosing, the antibacterial activities of
aminoglycosides and quinolones are mainly dependent on the
cumulative daily dose of the drug or the area under the con-
centration-time curve (AUC). We therefore set out to explore
whether the same pharmacodynamic indices (PDIs) that ex-
plain efficacy during monotherapy would explain efficacy dur-
ing combination therapy. Two approaches were applied to
evaluations of efficacy in a Pseudomonas aeruginosa animal
infection model. First, the efficacies of various dosing regimens
with combinations were determined and multiple regression
analysis was used to determine which PDIs most contributed
significantly to the model. Alternatively, the efficacies of agents
given singly were described as a function of the PDI most
appropriate for each agent in a regression model. The effica-
cies of the combination regimens were then predicted on the
basis of a linear combination of these regression models for the
single agents and predictions were compared with the outcome
of combination therapy.
(Part of these results were presented at the 38th Interscience
Conference on Antimicrobial Agents and Chemotherapy of
the American Society for Microbiology, San Diego, Calif., 24
to 27 September 1998.)
MATERIALS AND METHODS
Strain and animal model. P. aeruginosa ATCC 27853 was used in all experi-
ments. The MICs were 8 mg/liter for ticarcillin, 2 mg/liter for ceftazidime, 0.5
mg/liter for tobramycin, 1 mg/liter for netilmicin, and 0.5 mg/liter for ciprofloxa-
cin. Efficacy experiments with a neutropenic thigh model were performed as
described earlier (8). Briefly, neutropenic mice were inoculated with approxi-
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mately 106 CFU of P. aeruginosa in the exponential phase of growth. Two hours
(time zero) after infection, treatment was started with antibiotics, either alone or
in combination; control animals received no treatment. Animals were killed at
0 h (controls) or after 24 h of therapy. The thighs were removed and homoge-
nized, and aliquots of serial 10-fold dilutions were plated. Efficacy was then
determined as the difference between the number of CFU expressed as the
change in the log10 CFU (DCFU) at time zero and 24 h. Thus, a negative DCFU
value indicates a decrease in the number of bacteria after the start of therapy. All
regimens were performed with two mice, while the efficacy obtained for one
mouse was the mean result for two infected thighs.
Dosing regimens. For ceftazidime, netilmicin, and ciprofloxacin, the single-
agent regimens were designed to cover the ranges of time.MIC, peak level, and
AUC with minimum interdependence. This would allow optimal discrimination
of the importance of the indices in the regression analyses. For the combination
regimens the same approach was taken, but in addition, the combinations were
chosen to minimize interdependence between the indices (six in total, three for
each drug) of the two drugs in the combination. Thus, dosing intervals were 1, 4,
12, and 24 h, while the total daily doses varied from low to high for each drug.
The single-agent regimens used were 25 mg/kg of body weight every 1 h (q1h)
to 2,400 mg/kg every 12 h (q12h) for ticarcillin (n 5 14 different regimens), 3.12
mg/kg q1h to 600 mg/kg q12h for ceftazidime (n 5 12), 1 mg/kg q1h to 48 mg/kg
every 24 h (q24h) for tobramycin (n 5 14), 0.83 mg/kg q1h to 160 mg/kg q24h for
netilmicin (n 5 12), and 1.04 mg/kg q1h to 200 mg/kg q24h for ciprofloxacin (n 5
15). These regimens were combined, yielding various combination regimens:
ceftazidime-netilmicin (n 5 60 different combination regimens), ceftazidime-
ciprofloxacin (n 5 59), netilmicin-ciprofloxacin (n 5 38), and ticarcillin-tobra-
mycin (n 5 41).
Pharmacokinetics in mice. The pharmacokinetics of the antimicrobial agents
were determined in mice by taking serum samples after the administration of
various doses as described previously (8, 26). A one-compartment open model
with an absorption phase (Kinfit; Mediware, Groningen, The Netherlands) was
fit to the data. The values obtained were used to simulate the concentrations over
time for the dosing regimens used and then to calculate the various PDIs.
Analysis. The following indices were determined for each regimen:
time.MIC, time.0.253 the MIC, time.43 the MIC, peak, level, AUC/MIC,
dosing frequency, dose, total dose, and their logarithmically transformed values.
Multiple regression analysis was used to determine the R2 values and regression
coefficients with respect to efficacy by using the SAS program (23). Forward and
backward selection procedures were used to determine the two (or more) indices
that best explained the efficacies of the combination regimens or the interaction
between indices. The two indices that best explained efficacy were used to obtain
a three-dimensional plot to describe the respective relationships. A three-dimen-
sional surface plot was fit by using a fifth-order polynomial and a low stiffness
(Statistica; Statsoft, Tulsa, Okla.) to obtain a qualitative impression of the lin-
earity of the relationship. Prediction of the efficacies of combination regimens
was done by linear combination of the various regression models for single-agent
therapy (11). The predicted values were then compared with the measured
values.
RESULTS
Single-agent regimens. Figure 1 shows the plots of DCFU as
a function of the PDIs that best explained the efficacy of the
antibiotic, as well as the coefficients for the models after linear
regression. The PDIs that best explained the efficacy of each
drug were obtained by multiple regression analysis of the sin-
gle-agent data and were time.0.253 the MIC for ticarcillin
and ceftazidime and log AUC for tobramycin, netilmicin, and
ciprofloxacin. It must be noted that for ceftazidime,
time.MIC was as explanatory as time.0.253 the MIC.
Combination therapy. Multiple regression analysis of the
efficacies of the combination regimens showed that for each
combination, two PDIs could explain most of the variation.
These were, by and large, the same PDIs that best explained
the variations for each of the agents given singly (Table 1).
Thus, for the combination ticarcillin and tobramycin, R2 was
0.517 if time.0.253 the MIC for ticarcillin was entered in the
model and increased to 0.850 if the log AUC of tobramycin was
entered next. Although in some cases additional PDIs could be
entered into the model with significance (F test), no clear
pattern was distinguishable and their additional value was lim-
ited. Interaction terms were not significant.
FIG. 1. Scatter plots and linear regressions for five antibiotics and their PDIs that best explain efficacy.
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Three-dimensional plot analysis confirmed these results. An
example of such a three-dimensional plot is shown in Fig. 2 for
tobramycin and ticarcillin. The datum points are concentrated
in a nearly flat surface plane as a function of the two PDIs that
each explains the efficacy of the single agent. The flatness of
the plane indicates that the efficacy of the combination is
dependent on a linear combination of the efficacies of the
single agents, as explained by their respective predictive PDIs,
in this case, time.0.253 the MIC for ticarcillin and log AUC
for tobramycin. It also indicates that there is little interaction
between the PDIs. In the case of ciprofloxacin and netilmicin
one datum point was clearly outside the scatter region. This
was the result of a regimen in which both agents were admin-
istered q24h, thus, only once each. Because the results of an
analysis without this point yielded a superior final model, the
respective values of the model without this point are given in
parentheses in Table 1.
Prediction of efficacy. From the results described above, it
was hypothesized that the efficacies of the combinations could
be predicted or described by a linear combination of the effi-
cacy functions of the single-agent therapies, in which the inde-
pendent variable and the parameter values were those of the
PDI that best describes the efficacy of each drug. Thus, the
parameter values shown in Fig. 1 for each drug were used to
predict the efficacy of the combination. Figures 3a to d show
the plots of the predicted efficacy of each combination regimen
versus the actually observed values. Alternatively, for each
combination, a similar prediction was made on the basis of
AUC/MIC which has been advocated by some investigators
(24) as a sort of universal predictor for combination therapy. It
can be observed that for the beta-lactam combinations,
time.0.253 the MIC clearly explains efficacy during combi-
nation therapy (as is the case for monotherapy) but AUC/MIC
does not. Use of the latter value results in correlations which
are hardly, if at all, significant.
DISCUSSION
In this report we show that the PDI of a certain antimicro-
bial agent which is predictive of efficacy in an in vivo model of
infection is also predictive of efficacy of combination therapy.
Multiple regression analysis of the various PDIs with respect to
the efficacies of the various combination regimens showed that
two PDIs explained most of the variation for each combina-
tion. These were the same two indices that each characterized
the efficacy of single-agent therapy. Alternatively, the results of
combination therapy were adequately predicted by the effica-
cies of each of the single-agent therapies in that there was a
good correlation between the predicted values and the ob-
served values.
In the regression analyses of the combination regimens con-
taining a beta-lactam, the time.0.253 the MIC was consis-
tently more predictive than time.MIC. This could have been
because the MIC of the beta-lactam for the P. aeruginosa strain
is lower in the presence of another antibiotic. By applying the
recently described method of White et al. (28) with the E test,
it was found for several strains that the MIC of ceftazidime was
indeed approximately 0.253 the MIC in the presence of to-
bramycin (9) and that this phenomenon could explain the
results obtained with various combination regimens in an in
vitro model. For the strain used in this study, the E test pro-
duced similar results (data not shown). Thus, the presence of
another antibiotic in addition to the beta-lactam infers some
degree of synergism, resulting in a lower MIC. However it must
be noted that while time.MIC and time.0.253 the MIC were
equally predictive of efficacy of the single-agent regimen for
ceftazidime, for ticarcillin time.0.253 the MIC best explained
the variation during both combination therapy and mono-
therapy.
FIG. 2. Three-dimensional plot of efficacy (in DCFU [indicated as D 10log
CFU in the figure]) as a function of time.0.253 the MIC of ticarcillin and log
AUC of tobramycin.
TABLE 1. Results of multiple regression analysis of various dosing regimens
Combination regimen Variable entered in model Partial R2 Model R2
Ticarcillin-tobramycin (n 5 41) Time.0.253 the MIC of ticarcillin 0.517 0.517
Log AUC for tobramycin 0.333 0.850
Ceftazidime-netilmicin (n 5 60) Time.0.253 the MIC of ceftazidime 0.522 0.522
Log AUC for netilmicin 0.193 0.715
Ceftazidime-ciprofloxacin (n 5 59) Log AUC for ciprofloxacin 0.614 0.614
Time.0.253 the MIC of ceftazidime 0.157 0.771
Ciprofloxacin-netilmicin (n 5 38) AUC for ciprofloxacin 0.525 (0.598)a 0.525 (0.598)
AUC for netilmicin 0.172 (0.217) 0.697 (0.815)
a The values in parentheses are the results of regression analysis without the outlying datum point.
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Regression analysis of the combination netilmicin and cip-
rofloxacin yielded somewhat different results. The single most
explanatory index for that combination was the sum of the
values of AUC/MIC. This is not surprising, since AUC has
been shown to be an important explanatory variable for both
agents (27). Without this index, forward selection of the vari-
ous variables resulted in the AUCs for both agents being se-
lected in the model.
FIG. 3. Observed versus predicted values of various dosing regimens for four antimicrobial combinations. (a to d) Predicted values based on the PDI that best
explains the efficacy of each antibiotic. (e to h) For the same combinations in panels a to d, respectively, predicted values based on the sum of values of AUC/MIC
(sum aucmic). t, time.
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From Fig. 3d and h it can be observed that one datum point
is clearly an outlier. This point is the efficacy of a once-daily
dose of both antibiotics, and the observed efficacy is less than
would be expected from the combination. Analysis without this
datum point yields a significantly better model (Table 1). The
most likely explanation is that q24h regimens result in concen-
trations which are too low for too long a time due to rapid
elimination of the antibiotics in mice, and regrowth of bacteria
occurs after a certain time (18). The use of agents in combi-
nation in q24h regimens has little additional effect since re-
growth will still occur. In pharmacodynamic terms, this means
that for dosing regimens with long intervals relative to the
elimination half-life it not only is the total dose or the AUC
which is predictive of the outcome but is also the time.MIC
(or better, the time,MIC). This is confirmed in other analyses,
in which it has been shown for aminoglycosides that
time.MIC is an additional important factor for prediction of
the efficacies of q24 regimens (19, 27).
If the results of combination therapy were solely a linear
combination of each of the expected efficacies of the single
agents, it would be expected that the intercepts of the regres-
sion lines would intersect the y (and x) axis at zero. However,
if Fig. 3a to d are closely observed, it appears that none of the
intercepts intersect the y axis at zero but intersect it at a
negative DCFU significantly different from zero. This is an
indication that the agents have some synergistic action with
each other, as was already indicated by the observation that
time.0.253 the MIC was more predictive of efficacy than
time.MIC for beta-lactams in the combination regimens. Def-
initions of synergism between antimicrobial agents which both
have killing effects has always been problematic (2, 7, 10, 15,
20, 25). In vitro, a fractional inhibitory concentration index
greater than 2 for checkerboard titration studies and more
than a 2-log killing of the most active agent in time-kill curve
studies are being used for that purpose (25), but both methods
have the limitation that synergism is determined with static
drug concentrations and the methods are difficult to apply to
agents with high killing rates. The method used in the study
described in this report offers another way to define synergism
between two antimicrobial agents which have different (or sim-
ilar) modes of action but in which the efficacy of the combina-
tion can be predicted by the response of each of the agents
given singly. In this model two antimicrobial agents show syn-
ergy if the intercept of the regression line of the predicted and
observed responses is significantly different from zero. Al-
though we are aware that this method is perhaps not an ideal
solution for all combinations of antibiotics, this definition has
the advantage that synergism can be expressed quantitatively;
it has the additional capability of taking the combined effects of
declining concentrations of the two drugs with different half-
lives into account and is based on the in vivo outcome.
The major disadvantage of this method is the labor involved
in the study, and at present, there is no easy laboratory test to
determine whether synergism against clinical strains is present.
For that purpose, more strains and animal models should be
analyzed. The method does, however, provide insight into the
general presence of synergy between certain combinations of
antibiotics.
Several investigators have tried to describe a universal ap-
proach of synergism. An excellent review can be found in the
work of Greco et al. (12). The two frameworks most widely
used are those of Bliss and the one originally described by
Loewe and later by Berenbaum and Greco et al. (12). Basi-
cally, by both approaches the effect is described as a function of
the concentrations of the two drugs, either as an interaction
model or as additivity with an interaction term. The interpre-
tation of the fractional inhibitory concentration index is based
on the latter model. Incorporation of our results in these
frameworks is difficult, because by our approach the final effect
is described by the addition of two effects which are described
by two different variables instead of one variable. Moreover,
the two frameworks mentioned above are based on a concen-
tration-effect relationship, while by our approach the time fac-
tor also plays a role. Intuitively, the approach taken resembles
the Loewe additivity model (12), in that we look at a term that
describes a difference between predicted values (obtained by
the addition of two values) and actually measured values. The
difference, then, would be the interaction term or synergy. The
significant difference that was found, however, was not depen-
dent on the value of the underlying variables but was depen-
dent on its mere presence, as indicated by the fact that the
intercept of the predicted versus measured relationship was
significantly different from zero (Fig. 3a to d) and the fact that
interaction terms did not significantly contribute to the model.
Another way to look at it is to see Fig. 3 as a two-dimensional
projection of the three-dimensional graph exemplified in Fig. 2
and perpendicular to that plane. The fact that this results in a
more or less linear relationship indicates the dosing regimen
independence of the synergism.
We conclude that the methods and results described in this
report provide a tool for determination of the presence of
synergism between antimicrobial agents and that dosing regi-
mens with combinations of antimicrobial agents can be opti-
mized in a manner similar to that used for single-agent regi-
mens. The results indicate that the synergy found is primarily
dependent on the presence of the second drug, irrespective of
the dosing regimen.
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